HistoRx (www.historx.com) is proviging Radiation Therapy Oncology Group (RTOG; www.rtog.org) researchers with access to its Aqua® technology for biomarker analysis. HistoRx intends to commercialize assays and reagents developed in the course of the alliance for clinical use as predictive diagnostics. RTOG, an NCI-funded clinical cooperative group, will investigate the relationship between specific protein biomarkers and clinical responsiveness in brain tumor patients using customized immunohistochemical assays.
